Skip to main content
OpenTrials
Completed

NCT Number: NCT03695081

Patient Pathway Pharmacist - Optimal Drug-related Care

Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vestfold Hospital Trust

Tønsberg, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hip fracture patients in Vestfold county, Norway

Exclusion criteria

  • Patients under 18 years
  • Terminally ill
  • Hip fracture patients who do not follow the standardized patient pathway at Vestfold Regional Hospital
  • Patients who do not consent to be included in the study

Treatment and study plan

Patient Pathway Pharmacist intervention

Procedure
  • Medication reconciliation at admission to hospital
  • Medication review post surgery
  • Optimised list of drugs in the discharge summary, in accordance with hospital procedures
  • Medication reconciliation, six weeks after discharge
  • Medication review, six weeks after discharge

Primary outcomes

  1. Discharge summary score

    Time frame: At discharge (estimated five days after fracture/inclusion)

    In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program

  2. Admission summary score

    Time frame: At hospital admission (estimated to be within 24 hours after fracture)

    In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note.

  3. Discharge summaries written in accordance with procedure

    Time frame: At discharge (estimated five days after fracture/inclusion)

    In the discharge summary, the section describing drugs should be in accordance with procedure.

  4. Number of inappropriate drugs at discharge

    Time frame: During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion)

    After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list).

Secondary outcomes

  1. Readmission

    Time frame: 30 days after discharge

    Patients who are readmitted to hospital is quantified

  2. Readmission

    Time frame: 90 days after discharge

    Patients who are readmitted to hospital is quantified

  3. Death

    Time frame: 30 days after discharge

    The number patients who dies is quantified

  4. Death

    Time frame: 90 days after discharge

    The number of patients who dies is quantified

Other outcomes

  1. Experience of current practice

    Time frame: Prior to or during the early start of the intervention

    A questionnaire will be distributed to all health care professionals involved in the treatment of hip fracture patients

  2. Experience of patient pathway pharmacist

    Time frame: Within three months after last included patient

    Focus groups or semi-structured interviews will be performed to assess the advantages and/or disadvantages of introducing a patient pathway pharmacist.

Sponsors and collaborators

Lead sponsor

Sykehuset i Vestfold HF

Other

Collaborators

  • Hospital Pharmacy Enterprise, South Eastern Norway

Registry information

Official study title

Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study

Important dates

Study start
2018
Primary completion
2019
Study completion
2023
First posted
Oct 3, 2018
Registry last updated
Jun 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.